Oragenics Inc . (NYSE American:NYSE:OGEN), a Florida-based biopharmaceutical company with a market capitalization of $3.88 million, has announced the termination of its President's employment agreement. The decision was disclosed in a regulatory filing with the Securities and Exchange Commission (SEC) on Friday.
In other recent news, Oragenics Inc. has entered into a sales agreement with Dawson James Securities Inc. for an at-the-market offering of its common stock, potentially reaching up to $10,000,000 in aggregate sales. The Florida-based biopharmaceutical company has also made significant strides in its operations, raising over $6 million throughout 2024, including a public offering that generated approximately $4.45 million.
Oragenics has granted stock options to its President J. Michael Redmond and Chief Financial Officer Janet Huffman under its 2021 Equity Incentive Plan. The company has also rescheduled its 2023 Annual Meeting of Shareholders from August to December 2024.
In terms of clinical developments, Oragenics has progressed with ONP-002, a product candidate for the treatment of concussions, which has passed FDA-required cardiotoxicity tests and shown no evidence of causing DNA damage or genotoxicity in preclinical studies. These milestones mark critical safety validations for ONP-002 before proceeding to Phase II trials.
The company has also strengthened its leadership team with the appointments of Dr. William 'Frank' Peacock as Chief Clinical Officer and Dr. James 'Jim' Kelly as Chief Medical (TASE:PMCN) Officer, both of whom will oversee the upcoming Phase II trial.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.